Smoking and early infliximab response in Crohn's disease: A meta-analysis

Journal of Crohn's and Colitis

Volumn 9, Issue 2, 2015, Pages 140-146

  Inamdar, Sumant ^a   Volfson, Ariy ^a   Rosen, Lisa ^b   Sunday, Suzanne ^b   Katz, Seymour ^c   Sultan, Keith ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's disease; Infliximab; Smoking

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT;

ARTICLE; CORRELATIONAL STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY ASSESSMENT; DRUG RESPONSE; HARVEY BRADSHAW INDEX; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTEMATIC REVIEW; ADVERSE EFFECTS; REMISSION;

CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; REMISSION INDUCTION; SMOKING;

EID: 84953852105     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju018     Document Type: Article

References (31)

1. Lakatos P-L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12:6102-8
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
6. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59, quiz 660
7. Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003;17:1451-7
8. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
9. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A populationbased case control study of potential risk factors for IBD. Am J Gastroenterol 2006;101:993-1002
10. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989;34:1841-54
11. Logan RF, Edmond M, Somerville KW, Langman MJ. Smoking and ulcerative colitis. Br Med J (Clin Res Ed) 1984;288:751-3
12. Somerville KW, Logan RF, Edmond M, Langman MJ. Smoking and Crohn's disease. Br Med J (Clin Res Ed) 1984;289:954-6
13. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-71
14. Lakatos PL, Vegh Z, Lovasz BD, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013;19:1010-7
15. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-31
16. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8
17. Palli D, Trallori G, Saieva C, et al. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut 1998;42:175-9
18. Narula N, Fedorak RN. Does smoking reduce infliximab's effectiveness against Crohn's disease? Can J Gastroenterol 2009;23:121-5
19. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;8:357-63
20. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005;37:577-83
21. Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005;22:613-26
22. Laharie D, Salzmann M, Boubekeur H, et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005;29:145-9
23. Luna-Chadid M, Pérez Calle JL, Mendoza JL, et al. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig 2004;96:379-81; 382-4
24. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-13
25. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63
26. Martínez-Borra J, López-Larrea C, González S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6
27. Siegel CA, Finlayson SRG, Sands BE, Tosteson ANA. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10:46-51
28. Nunes T, Etchevers MJ, Domènech E, et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther 2013;38:752-60
29. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71
30. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
31. Bergeron V, Grondin V, Rajca S, et al. Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis 2012;18:1101-11